ALK and non-small cell lung carcinoma: In NSCLC, the most common alteration detected is a translocation with another partner gene leading to a fusion between the kinase domain of ALK and the amino-terminal portion of different protein partners, promoting the activation of downstream signaling pathways, and resulting in increased proliferation and cell survival.